Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

Wilex's Heidelberg Pharma GmbH subsidiary exercised an option under a 2016 deal to license humanized antibodies against tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17; CD26...